224 related articles for article (PubMed ID: 17488727)
21. Altered expression of carbonic anhydrase-related protein XI in neuronal cells expressing mutant ataxin-3.
Hsieh M; Chang WH; Hsu CF; Nishimori I; Kuo CL; Minakuchi T
Cerebellum; 2013 Jun; 12(3):338-49. PubMed ID: 23184527
[TBL] [Abstract][Full Text] [Related]
22. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
23. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
24. Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.
Colomer Gould VF
NeuroRx; 2005 Jul; 2(3):480-3. PubMed ID: 16389311
[TBL] [Abstract][Full Text] [Related]
25. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
26. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.
Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V
J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899
[TBL] [Abstract][Full Text] [Related]
27. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
28. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Yoshizawa T; Yamagishi Y; Koseki N; Goto J; Yoshida H; Shibasaki F; Shoji S; Kanazawa I
Hum Mol Genet; 2000 Jan; 9(1):69-78. PubMed ID: 10587580
[TBL] [Abstract][Full Text] [Related]
29. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
30. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.
Jung J; Xu K; Lessing D; Bonini NM
Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548
[TBL] [Abstract][Full Text] [Related]
31. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.
Rüb U; de Vos RA; Brunt ER; Sebestény T; Schöls L; Auburger G; Bohl J; Ghebremedhin E; Gierga K; Seidel K; den Dunnen W; Heinsen H; Paulson H; Deller T
Brain Pathol; 2006 Jul; 16(3):218-27. PubMed ID: 16911479
[TBL] [Abstract][Full Text] [Related]
32. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
[TBL] [Abstract][Full Text] [Related]
33. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD.
Jana NR; Nukina N
Neurotox Res; 2004; 6(7-8):523-33. PubMed ID: 15639784
[TBL] [Abstract][Full Text] [Related]
34. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
[TBL] [Abstract][Full Text] [Related]
35. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.
Evers MM; Toonen LJ; van Roon-Mom WM
Mol Neurobiol; 2014 Jun; 49(3):1513-31. PubMed ID: 24293103
[TBL] [Abstract][Full Text] [Related]
36. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.
Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P
Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362
[TBL] [Abstract][Full Text] [Related]
37. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
38. Differential susceptibility of cultured cell lines to aggregate formation and cell death produced by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Yoshizawa T; Yoshida H; Shoji S
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):349-52. PubMed ID: 11719271
[TBL] [Abstract][Full Text] [Related]
39. CREB-binding protein sequestration by expanded polyglutamine.
McCampbell A; Taylor JP; Taye AA; Robitschek J; Li M; Walcott J; Merry D; Chai Y; Paulson H; Sobue G; Fischbeck KH
Hum Mol Genet; 2000 Sep; 9(14):2197-202. PubMed ID: 10958659
[TBL] [Abstract][Full Text] [Related]
40. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease.
Chang WH; Tien CL; Chen TJ; Nukina N; Hsieh M
Neurosci Lett; 2009 Apr; 454(2):152-6. PubMed ID: 19429074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
